This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Case Study – Unidose Nasal Spray Pump for Epilepsy
Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Drug Repositioning – Benefits and Challenges for Lifecycle Management
Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation
Step to Success in Nose-to-Brain Drug Delivery
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
